PDCD1 and neoplasm: Nivolumab blocks programmed cell death protein 1 (PD-1) interactions on T cells with programmed death ligand 1 (PD-L1) on tumor cells, and ipilimumab inhibits cytotoxic T lymphocyte–associated protein 4 (CTLA-4) to enhance T cell activation.